SCHEMBL1150252

SCHEMBL1150252

COc1ccc2c(n1)CC(=O)N2c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.46
OPRK1 P41145 1/20 0.43
PDE4D Q08499 1/20 0.43
GAA P10253 7/20 0.42
ALDH1A1 P00352 7/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PKM P14618 1/20 0.38
TLR9 Q9NR96 1/20 0.38
MAPT P10636 4/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
TSHR P16473 1/20 0.36
PTGS1 P23219 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1149585 0.77 GAA (0.51) HPGDGAAALDH1A1L3MBTL1KDM4E
SCHEMBL1149935 0.72 HPGD (0.51) HPGDOPRK1PDE4DGAAALDH1A1
SCHEMBL1149924 0.72 HPGD (0.51) HPGDOPRK1PDE4DGAAALDH1A1
SCHEMBL1150266 0.71 HPGD (0.57) HPGDOPRK1PDE4DGAAALDH1A1
SCHEMBL1144467 0.70 HPGD (0.67) HPGDOPRK1PDE4DGAAALDH1A1
SCHEMBL5370733 0.69 HTR7 (0.35) HPGDCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5372018 0.69 BMPR1B (0.39) HPGDALDH1A1L3MBTL1KDM4EMEN1
SCHEMBL4422153 0.69 HPGD (0.74) HPGDOPRK1PDE4DGAAALDH1A1
SCHEMBL24834476 0.68 ALDH1A1 (0.50) HPGDGAAALDH1A1L3MBTL1KDM4E
SCHEMBL6073495 0.67 CYP11B2 (0.42) CYP1A2CYP3A4PKMSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580813-B2 Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals SANOFI (FR) 2013-11-12 US disclosed
EP-2240482-B1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-07-17 EP disclosed
US-20110039861-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-02-17 US disclosed
EP-2240482-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2010-10-20 EP disclosed
WO-2009095162-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039861-A1 CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS REN, PM20D2, CDK20 HPGD 1256/4885OPRK1 1056/4885PDE4D 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.